Cannara Biotech Statistics
Total Valuation
Cannara Biotech has a market cap or net worth of 135.20 million. The enterprise value is 148.66 million.
| Market Cap | 135.20M |
| Enterprise Value | 148.66M |
Important Dates
The last earnings date was Monday, January 26, 2026.
| Earnings Date | Jan 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 98.78M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.18% |
| Shares Change (QoQ) | +3.00% |
| Owned by Insiders (%) | 5.64% |
| Owned by Institutions (%) | 0.22% |
| Float | 43.80M |
Valuation Ratios
The trailing PE ratio is 15.99 and the forward PE ratio is 10.79.
| PE Ratio | 15.99 |
| Forward PE | 10.79 |
| PS Ratio | 1.68 |
| PB Ratio | 1.70 |
| P/TBV Ratio | 1.70 |
| P/FCF Ratio | 15.26 |
| P/OCF Ratio | 8.53 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.53, with an EV/FCF ratio of 16.78.
| EV / Earnings | 17.59 |
| EV / Sales | 1.80 |
| EV / EBITDA | 7.53 |
| EV / EBIT | 10.04 |
| EV / FCF | 16.78 |
Financial Position
The company has a current ratio of 2.70, with a Debt / Equity ratio of 0.31.
| Current Ratio | 2.70 |
| Quick Ratio | 1.01 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 1.30 |
| Debt / FCF | 2.81 |
| Interest Coverage | 6.06 |
Financial Efficiency
Return on equity (ROE) is 11.70% and return on invested capital (ROIC) is 10.74%.
| Return on Equity (ROE) | 11.70% |
| Return on Assets (ROA) | 7.51% |
| Return on Invested Capital (ROIC) | 10.74% |
| Return on Capital Employed (ROCE) | 14.14% |
| Weighted Average Cost of Capital (WACC) | 5.91% |
| Revenue Per Employee | 177,752 |
| Profits Per Employee | 18,702 |
| Employee Count | 452 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 1.37 |
Taxes
In the past 12 months, Cannara Biotech has paid 3.79 million in taxes.
| Income Tax | 3.79M |
| Effective Tax Rate | 30.95% |
Stock Price Statistics
The stock price has increased by +60.42% in the last 52 weeks. The beta is 0.28, so Cannara Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | +60.42% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 1.13 |
| Relative Strength Index (RSI) | 59.08 |
| Average Volume (20 Days) | 8,938 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cannara Biotech had revenue of 80.34 million and earned 8.45 million in profits. Earnings per share was 0.09.
| Revenue | 80.34M |
| Gross Profit | 34.45M |
| Operating Income | 14.41M |
| Pretax Income | 12.24M |
| Net Income | 8.45M |
| EBITDA | 19.01M |
| EBIT | 14.41M |
| Earnings Per Share (EPS) | 0.09 |
Balance Sheet
The company has 11.82 million in cash and 24.91 million in debt, with a net cash position of -13.09 million.
| Cash & Cash Equivalents | 11.82M |
| Total Debt | 24.91M |
| Net Cash | -13.09M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 79.61M |
| Book Value Per Share | 0.84 |
| Working Capital | 38.32M |
Cash Flow
In the last 12 months, operating cash flow was 15.85 million and capital expenditures -6.99 million, giving a free cash flow of 8.86 million.
| Operating Cash Flow | 15.85M |
| Capital Expenditures | -6.99M |
| Free Cash Flow | 8.86M |
| FCF Per Share | n/a |
Margins
Gross margin is 42.88%, with operating and profit margins of 17.93% and 10.52%.
| Gross Margin | 42.88% |
| Operating Margin | 17.93% |
| Pretax Margin | 15.24% |
| Profit Margin | 10.52% |
| EBITDA Margin | 23.66% |
| EBIT Margin | 17.93% |
| FCF Margin | 11.03% |
Dividends & Yields
Cannara Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.18% |
| Shareholder Yield | -2.18% |
| Earnings Yield | 6.25% |
| FCF Yield | 6.55% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Cannara Biotech has an Altman Z-Score of 2.65 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.65 |
| Piotroski F-Score | 8 |